Pancreatic cancer (PC) is one of the leading causes of cancer-related mortality worldwide, with 5-year relative survival of only 8%. The predicted death rates have progressively increased over the past years ([@bib24]). This unfavourable trend emphasises the importance of giving priority to research in PC prevention and treatment. Number of deaths by PC in 2014 in the European Union (EU) has been estimated to 82 300 cases equally distributed in men and women. By analogy, a similar prediction has been reported for women with breast cancer (*N*=89 300) ([@bib19]).

Most PCs are unresectable due to the presence of either distant metastases or locoregional metastases, including vascular invasion (locally advanced PC: LAPC). At the time of diagnosis, up to 35% of patients with PC present with locally advanced disease ([@bib21]). The management of those patients is still controversial, specifically the role of radiotherapy remains uncertain ([@bib16]; [@bib17]; [@bib5]; [@bib18]; [@bib21]; [@bib12]).

Currently, there is a lack of staging system and consensus regarding specific risk profile for overall survival (OS) in LAPC, which can lead to confusion in research strategies development and potentially inappropriate management of patients. Given this aspect and the current interest in precision medicine, there is a need for prognostic tools to optimise patients\' selection for appropriate treatment therapy in order to achieve more personalised management. Specifically, more accurate prediction of OS at diagnosis may help to ensure well-balanced arms in clinical trials and to a better management patient care in the future. Ultimately, such a tool may lead to improve patient\'s health-related quality of life (HRQoL), chemotherapy (CT) cost-effectiveness ratio, and design of future clinical trials.

Nomograms have been increasingly used for survival prediction in different cancer settings as an alternative to traditional TNM staging system or a new standard ([@bib2]). Unfortunately, no single study evaluating a nomogram for survival prediction in LAPC patients is available.

We aimed to develop and validate a new prognosis model, nomogram and score for OS using a broad spectrum of parameters currently available at baseline. This model was developed based on a large cohort of LAPC patients enrolled in the phase III LAP07 trial and validated in patients encountered in daily clinical practice.

Patients and Methods
====================

Patients
--------

The development cohort was obtained from an international, multicentre, randomised phase III LAP07 trial (ClinicalTrials.gov NCT00634725). The complete design and trial procedures of the LAP07 study was previously described ([@bib13]). Briefly, the LAP07 study assessed whether chemoradiotherapy (CRT) administered to LAPC patients whose tumour has been controlled after 4 months of gemcitabine alone or plus erlotinib induction CT increases OS compared with continuation of the same CT. In this trial, CRT did not increase OS compared with the continuation of CT alone. Demographics, cancer history, clinicopathological, biological and radiological parameters at baseline as well as treatment outcomes were collected.

The external validation cohort included 106 consecutive LAPC patients treated at the University Hospital of Besançon, France between January 2003 and December 2013.

Main eligibility and exclusion criteria along with treatment and procedures for the development and validation cohorts are specified in [Supplementary Appendix A1](#sup1){ref-type="supplementary-material"}.

Follow-up
---------

In the development cohort, patients were observed at 2, 4, 7, 9 and 11 months and every 2 months thereafter. At each follow-up visit, a detailed clinical history and a complete physical examination were carried out. Database was locked on 23 February 2014.

In the validation cohort, patients were treated using standard clinical protocols. A radiological evaluation was performed every 3 months. Database was locked on 13 November 2015.

Statistical analysis
--------------------

The primary analysis was performed on the LAP07 intent to treat population. Mean (s.d.) values and frequency (percentage) were provided for the description of continuous and categorical variables, respectively. Means and proportions were compared using Student\'s *t*-test and χ^2^-test (or Fisher\'s exact test, if appropriate), respectively.

In the development cohort, OS was calculated from the date of study randomisation to the date of death from any cause. Patients last known to be alive were censored at the time of their last follow-up assessment ([@bib3]). In the external validation cohort, the starting point for OS was the date of diagnosis of LAPC. OS was estimated using the Kaplan--Meier method and described using median or rate at specific time points with 95% confidence intervals (95% CI). Follow-up was calculated using a reverse Kaplan--Meier estimation when feasible ([@bib23]).

Cox-proportional-hazard models were performed to estimate the hazard ratio (HR) and 95% CI for factors associated with OS. The association of the baseline parameters with OS was first assessed using univariate Cox analyses, and then those with *P*\<0.10 were entered into a final multivariate Cox regression model. Significantly skewed continuous variables, such as neutrophil count, total bilirubin, alkaline phosphatase, aspartate transaminase, alanine aminotransaminase, lactate dehydrogenase, albumin and cancer antigen 19.9 (CA 19-9), were normalised by logarithmic transformation. Hazard proportionality was checked by plotting log-minus-log survival curves and by the cumulative martingale process plots. Log-linearity assumption for continuous variables was also checked graphically by making a categorical variable. For continuous variables involved in the final multivariate model, a fractional polynomial method was applied to validate the transformation used and to assess the relationship between predictors and survival. In the absence of clinical hypothesis and/or documentation in the literature, no interaction term was considered in the model construction.

Accuracy of the final model was verified regarding two parameters: discrimination and calibration. The predictive value and the discrimination ability (that is, the ability to separate patients with different prognosis) of the final model were evaluated with the Harrell\'s concordance index (C-index) ([@bib14]). One thousand random samples of the population were used to derive 95% CI for the C-statistic. Calibration and goodness of fit refers to the ability to provide unbiased survival predictions in groups of similar patients. These were assessed by visual examination of calibration plot and tested with an extension of the Hosmer--Lemeshow test for survival data. Internal validation of the final multivariate model was performed with a bootstrap sample procedure.

The final model was used to derive a nomogram allowing the estimation of median and individual post-diagnosis OS probabilities at 6, 12, 24 and 48 months. For estimation at population level, a prognostic score was constructed and weighted with *β*-coefficients estimations in the final model, and normalised between 0 and 5. To give a reasonable spread of risk, we chose to work on two and three prognostic risk groups. In such way, different cut points for the risk score from the development set were explored. These were based on the optimal cut point ([@bib15]) and Cox\'s ([@bib7]) methods for the two- and three-risk groups approach, respectively. Median and tertiles were also considered. The discrimination abilities of the different prognostic scores produced were assessed with the Harrell\'s concordance index (C-index) by considering risk groups classification.

Patients\' baseline key characteristics were compared between prognostic risk groups using Fisher-exact test and the Kruskal--Walis test for categorical and quantitative parameters, respectively.

To explore the performance of the final model, sensitivity analyses were performed by forcing the treatment assigned at first randomisation (gemcitabine *vs* gemcitabine plus erlotinib) to enter into the model and by including baseline histological grade and systolic blood pressure; two parameters that were not initially selected in the multivariate analysis process due to their high rate of missing data. To assess potential bias arising from missing data for parameters involved in the multivariate final model on their significance (*P*-value) and estimates (β and its standard error), a multiple imputation procedure with a Markov chain Monte Carlo method was performed using SAS MI and MIANALYZE procedure.

The final multivariate and the prognostic score discrimination abilities were confirmed in an external validation cohort and evaluated with the Harrell\'s concordance index (C-index) with survival predictions from the model and from risk groups classification, respectively. To identify risk groups and to determine their survival profile, the same development cohort-derived risk predictive algorithm was applied.

All analyses were performed using SAS version 9.3 (SAS Institute) and R software version 2.15.2 (R Development Core Team; <http://www.r-project.org>). Values of *P*\<0.05 were considered statistically significant and all tests were two-sided. Details on the interpretation of important statistical concepts are given in [Supplementary Appendix A2](#sup1){ref-type="supplementary-material"}.

Results
=======

Patient characteristics
-----------------------

A total of 442 LAPC patients treated in the LAP07 trial between February 2008 and December 2011 formed the development cohort. The median follow-up time was 34.3 months (95% CI, 27.6--43.7). Overall, 106 LAPC patients treated in the University Hospital of Besançon between January 2003 and December 2013 were included in the external validation cohort. Patient baseline characteristics according to the cohort set are summarised in [Table 1](#tbl1){ref-type="table"}. As expected, given its daily clinical nature the validation cohort differed from the LAP07 population with respect to, age, histological grade, WHO-PS, tumour size and treatment regimens.

Prognostic factors for OS
-------------------------

Only 8 out of 30 evaluated baseline parameters were associated with OS in the univariate Cox analyses with a *P*\<0.1. These were age, histological grade, performance status (the World Health Organization scale), systolic blood pressure, pain, albumin level, tumour size and CA 19-9 ([Table 2](#tbl2){ref-type="table"}). The multivariate Cox analysis (*N*=358) showed five independent risk factors for OS: age; pain; albumin; tumour size; and CA 19-9 ([Table 3](#tbl3){ref-type="table"}).

Performance assessment and internal validation of the final model
-----------------------------------------------------------------

The multivariate model exhibited acceptable discrimination ability (C-index 0.60; 95% bootstrap percentile CI, 0.57--0.64) and a good calibration at 6, 12, 24 and 48 months (*P*=0.99, *P*=0.55, *P*=0.30, and *P*=0.08, respectively). The calibration plots showed an optimal agreement between model prediction and actual observation for predicting OS probability at 6, 12, 24, and 48 months ([Figure 1](#fig1){ref-type="fig"}).

In the internal validation, uncertainties around HR measured with the bootstrapping procedure ([Table 3](#tbl3){ref-type="table"}) reflected the robustness of the final model.

Sensitivity analyses
--------------------

In the sensitivity analysis, the performance of the final model was investigated by forcing the allocated treatment (gemcitabine *vs* gemcitabine plus erlotinib). Associations remained unchanged ([Supplementary Appendix Table A1A](#sup1){ref-type="supplementary-material"}).

After adjustment of the final model for histological grading and systolic blood pressure, main associations of the final multivariate model remained unchanged except for CA 19-9 ([Supplementary Appendix Table A1B](#sup1){ref-type="supplementary-material"}).

The final multivariate model was based on 358 (81.0%) patients (complete-subject analysis) for whom the five parameters were available. A multiple imputation analysis based on 1000 imputed data sets for all the variables provided similar results to the complete-subject analysis in term of significance for the association (*P*-value) and for coefficient estimations (β and SE) ([Supplementary Appendix Table A1C](#sup1){ref-type="supplementary-material"}).

Prognostic nomogram for OS
--------------------------

Nomogram integrating all significant independent factors for OS was built ([Figure 2](#fig2){ref-type="fig"}). An illustration and details on the nomogram development are provided in [Supplementary Appendix A3](#sup1){ref-type="supplementary-material"}.

Prognostic score for death-risk stratification
----------------------------------------------

A PROLAP (**PR**ognostic score for **O**verall survival in **LAP**C) score ranging from 0 to 5 based on the final model was calculated for each patient. All factors included in the score were weighted according to the β-parameter estimation issued from the final Cox model. The contribution of each individual factor was summed to generate a raw score that was finally applied to normalisation between 0 and 5. This score construction and equation are provided as [Supplementary Appendix A3](#sup1){ref-type="supplementary-material"}.

On the basis of an optimal cut point determined by Hothorn and Lausen method ([Supplementary Appendix Figure A1](#sup1){ref-type="supplementary-material"}) patients were categorised into two-risk groups with significantly different prognostic profiles ([Figure 3A](#fig3){ref-type="fig"}): a low-risk group (*N*=242, score\<2.455) and a high-risk group (*N*=116, score ⩾2.455, HR=2.01 95% CI, 1.58--2.56; *P*\<0.0001). The median OS was 14.7 and 9.4 months for the low-risk group and the high-risk group, respectively (*P*\<0.0001).

Considering that the prognostic score assumes a normal distribution (mean=2.27; s.d.=0.39) for the three-risk groups approach, Cox demonstrated that the loss of information from grouping would be minimised by selecting cut points equal to 2.291 and 2.720. Such grouping achieved a clear separation of the Kaplan--Meier curves ([Figure 3B](#fig3){ref-type="fig"}). The median OS was 15.3, 11.7 and 8.5 months for the low, intermediate and the high-risk groups, respectively (*P*\<0.0001).

Results for classification of patient\'s into two- and three-risk groups related to the median and tertiles approach are provided in [Supplementary Appendix Figure A2](#sup1){ref-type="supplementary-material"}. These, however, were not selected as the main result given the low efficiency of this approach.

Baseline characteristics of patients according to the risk groups
-----------------------------------------------------------------

For the two-risk group approach, in the high-risk group, 75% of patients presented with pain, were older, with moderate albumin level and had tumour of large size. In contrast, in the low-risk group, 48% of patients reported pain, were younger, had normal albumin levels and had tumour of small size ([Supplementary Appendix Table A1A](#sup1){ref-type="supplementary-material"}). A similar trend across groups was observed in the three-risk groups approach ([Supplementary Appendix Table A1B](#sup1){ref-type="supplementary-material"}).

Agreement between nomogram prediction and the PROLAP score
----------------------------------------------------------

Given that the prognostic nomogram and score were built from the same multivariate final model parameters, they can be connected. Characterisation of risk groups with the total number of points derived from the nomogram is provided in the Kaplan--Meir curves ([Figure 3A and B](#fig3){ref-type="fig"}).

Predictive value of treatments on OS according to the risk groups
-----------------------------------------------------------------

In the two- and three-risk group approaches, there were no differential effects on OS of the gemcitabine-erlotinib combination across groups. In addition, no significant OS difference was observed in favour of CRT over CT across groups.

Interestingly, a total of 121 (68%) low-risk, 85 (62%) intermediate-risk and 19 (44%) high-risk patients reached the second randomisation (*P*=0.0027). A similar significant trend was also observed in the two-risk group analysis. Detailed results are provided in [Supplementary Appendix A4](#sup1){ref-type="supplementary-material"}.

Validation of the discriminatory ability of the PROLAP score
------------------------------------------------------------

A total of 63 (59%) of patients from the external validation cohort had all the information required to be eligible for the score calculation using five baseline parameters (pain, CA 19-9, albumin, tumour size and age). Similar characteristics at diagnosis and outcomes were observed between eligible and non-eligible patients ([Supplementary Appendix Table A2](#sup1){ref-type="supplementary-material"}).

Overall, the final multivariate model identified in the development set exhibited a better discrimination ability in the validation cohort (C-index 0.68; 95% bootstrap percentile CI, 0.59--0.77).

In the two-risk group approach, the discrimination ability of the risk score algorithm developed in the main analysis was externally confirmed, with median OS estimated to 17.1 months for the low-risk group and 9.2 months for the high-risk group (HR=2.3; 95% CI, 1.3 to 4.2; log-rank *P*=0.003; [Figure 3C](#fig3){ref-type="fig"}) and with a better C-index estimation (0.61; 95% CI 0.54 to 0.68) than in the development cohort.

Similarly in the three-risk group approach, the discrimination ability of the risk score was externally confirmed, with median OS estimated to 18.3 months for the low-risk group, 14.1 months for the intermediate-risk group and 7.6 months for the high-risk group (log-rank *P*\<0.0001; [Figure 3D](#fig3){ref-type="fig"}) and with a better C-index estimation (0.68; 95% CI 0.59--0.76) than in the development cohort.

Discussion
==========

Currently, there is no efficient prognostic staging system that could help to estimate OS at diagnosis in LAPC patients. On the basis of the largest phase III clinical trial of LAPC, we established a novel easy-to-use survival prediction model built on five key parameters (age, albumin, tumour size, CA 19-9 and pain) and provided a prognostic nomogram and score.

Nomograms are an important component of modern medical decision-making ([@bib2]). The main goal of such staging systems is to provide the most accurate predictions for specified end points. In this way, parameters to consider should be easily available and measurable. The proposed nomogram fulfils these requirements and produces individual survival estimations in LAPC patients. The baseline prognostic score can be considered as a complementary tool for clinical practice by producing a classification of the patients into well-identified death-risk populations. We have developed an open-access web site smartphone compatible to automatically compute the prognostic nomogram and score estimations. (<http://www.umqvc.org/en/tool/prolap.html>).

The present work revealed a considerable heterogeneity among LAPC patients regarding their OS-risk profiles. The recognition of risk groups with different prognostic outcomes may offer the opportunity to define risk-adapted strategies for LAPC management in the future. Indeed, while our analysis was based on OS, but not on progression-free survival, we accurately identified patients more likely not to be eligible for the second randomisation. Overall, 32% of the low-risk, 38% of the intermediate-risk and 56% of the high-risk patients failed to reach the second randomisation due to progression.

Our study supports the role of the nomogram and/or the PROLAP score as tools to be used both for patient selection and/or for patients\' stratification in future clinical trials. These may help to reduce heterogeneity among treatment arms in terms of risk profile and thus better estimate the treatment effect. Indeed, if patients from the risk groups identified are distributed unequally among arms this difference can lead to a distortion in the outcome analysis. It seems therefore reasonable to recommend pre-planned subgroup analyses according to the level of such a score in future trials.

It is worth noting that two of the five factors included in our model, pain and albumin are objective surrogates for measurement of HRQoL ([@bib4]). The importance of these parameters in the model and the recognition of HRQoL as an additional prognostic value for OS in metastatic disease ([@bib11]) and in other tumour types ([@bib8]; [@bib9]; [@bib20]) suggest that HRQoL needs to be evaluated in the future prognostic models for LAPC.

Our study has several strengths. The score was constructed in the framework of a large international multicentre trial with a broad spectrum of parameters available at diagnosis. Moreover, discrimination, calibration and internal validation underlined satisfactory performance and validity of the model. We built our model in a rigorous methodological framework respecting a recent recommended checklist for nomograms ([@bib2]) and providing a transparent reporting of the multivariate model as suggested in the TRIPOD statement ([@bib6]). The internal validation ensured a reliable performance for patients similar to those of the development cohort. Our prognostic score was fully externally replicated in the 'real-world\' patients encountered in daily clinical practice: different centres; clinicians; treatments; and periods. This external validation population is quite different to the development set and underlines the robustness of our results in the clinical setting. A validation in a larger cohort of patients will be performed with the International Pancreas Database Program ARCAD metabase, which is currently under development. Finally, the five parameters identified in our study reflect the general condition of the patient and disease activity and therefore provide clinically relevant information in LAPC. These factors are admitted prognostic factors in LAPC patients by clinicians and accordingly enhance the relevance of the tools developed.

The present study has also several limitations. The role of pain status could be further refined by its assessment at diagnosis before administration of analgesic or by documenting whether the patient was receiving opioids or not at the time of assessment. In case of baseline cholestasis, the CA 19-9 level should be better estimated after biliary drainage whenever possible in order to minimise overestimation. Despite the broad spectrum of parameters analysed and the acceptable performance of the score, we recognise that additional potentially relevant variables such as a neutrophil to lymphocyte ratio could not be assessed and merit future consideration ([@bib22]; [@bib25]; [@bib10]) given that novel biologic insights have recently been validated through the pancreatic genome project ([@bib1]).

In conclusion, we present here a novel OS prediction model based on five key independent prognostic factors at the time of diagnosis. This allowed us to develop and externally validate the first prognostic staging system for OS in LAPC and then to provide functional tools at individual (nomogram) and population (score) levels: <http://www.umqvc.org/en/tool/prolap.html>. In this study, we revealed considerable heterogeneity among LAPC patients regarding their OS-risk profiles with the recognition of clearly different risk groups. The prognostic nomogram and the score proposed may help to optimise clinical trials design and might offer the opportunity to define risk-adapted strategies for LAPC management in the future.
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![**Calibration plots at 6, 12, 24 and 48 months for the final multivariate model.** Vertical axis is the observed proportion of patients surviving at time of interest.](bjc2016212f1){#fig1}

![**Prognostic nomogram to predict individual overall survival probability in patients with locally advanced pancreatic cancer.** Points are assigned for each risk factor by drawing a line upward from the corresponding values to the 'point\' line. The total sum of points for four risk factors is plotted on the 'total points\' line. A line is drawn down to read the corresponding predictions of 6-, 12-, 24- and 48-month-survival probability and median survival time. For example, a patient with the following characteristics--63 years old (26 points), tumour measurement equal to 105 mm (53 points), albumin at 40.9 g l^−1^ (46 points), CA 19-9 at 89 (log-value=1.95; 39 points) and the presence of pain at baseline clinical exam (16 point) will have a total points of 180, which corresponds to 6-, 12-, 24- and 48-month-survival probabilities of 80% (95% CI 71--86), 40% (95% CI 25--55), 7% (95% CI 2--17) and 1% (95% CI 0--4) and a predicted median survival time of 10.5 months (95% CI 8.75--13.5). An online web-based application smartphone compatible was developed that provides individualised survival estimates from the nomogram: <http://www.umqvc.org/en/tool/prolap.html>.](bjc2016212f2){#fig2}

![**Kaplan--Meier curves of overall survival for (A, B) the development set cohort and (C, D) the external validation set cohort according to prognostic score group for the Hothorn & Lausen optimal cut point (A, C) and Cox\'s methods (B, D) for the two- and three-risk groups approach, respectively.** An online web-based smartphone compatible application was developed that provides risk-group classification for OS from the PROLAP score: <http://www.umqvc.org/en/tool/prolap.html>.](bjc2016212f3){#fig3}

###### Baseline characteristics according to the cohort set

                                                        **Development set cohort--LAP07 trial (*****N*****=442)**                    **External validation set cohort--University Hospital of Besan**ç**on cohort (*****N*****=106)**                   ***P***
  ---------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------
  Age, years[a](#t1-fn2){ref-type="fn"}                                         63.5±9.6                                                                                        67.1±10.2                                                               **0.0007**
  Gender, *N* (%)                                                                                                                                                                                                                                        
   Male                                                                         228 (52%)                                                                                        57 (54%)                                                                
   Female                                                                       214 (48%)                                                                                        49 (46%)                                                               0.7456
  Localisation, *N* (%)                                                                                                                                                                                                                                  
   Head/head and body                                                           302 (69%)                                                                                        71 (70%)                                                                
   Other (body and/or tail)                                                     138 (31%)                                                                                        31 (30%)                                                               0.9059
   Unknown                                                                          2                                                                                               4                                                                    
  Grading, *N* (%)                                                                                                                                                                                                                                       
   Well differentiated                                                          107 (48%)                                                                                        9 (26%)                                                                 
   Moderately differentiated                                                    75 (34%)                                                                                         17 (50%)                                                                
   Poorly differentiated                                                        41 (18%)                                                                                         8 (24%)                                                                **0.05556**
   Missing                                                                         219                                                                                              72                                                                   
  Lymph nodes, *N* (%)                                                                                                                                                                                                                                   
   Yes                                                                          179 (41%)                                                                                          ---                                                                   
   No                                                                           258 (59%)                                                                                          ---                                                                   
   Missing                                                                          5                                                                                              ---                                                                   
  WHO-PS, *N* (%)                                                                                                                                                                                                                                        
   0                                                                            197 (46%)                                                                                        31 (30%)                                                                
   1                                                                            203 (47%)                                                                                        59 (56%)                                                                
   2                                                                             31 (7%)                                                                                         14 (13%)                                                                
   3                                                                             0 (0%)                                                                                           1(1%)                                                                 **0.004892**
   Missing                                                                         11                                                                                               1                                                                    
  RECIST tumour size (mm)[a](#t1-fn2){ref-type="fn"}                            44.0±18.0                                                                                       38.3±14.7                                                               **0.00385**
   Missing                                                                         20                                                                                               9                                                                    
  RECIST tumour size (mm), N (%)                                                                                                                                                                                                                         
   \<30                                                                         66 (16%)                                                                                         22 (23%)                                                                
   30--50                                                                       226 (54%)                                                                                        56 (58%)                                                                
   ⩾50                                                                          130 (31%)                                                                                        19 (20%)                                                               **0.04676**
   Missing                                                                         20                                                                                               9                                                                    
  Vascular invasion, *N* (%)                                                                                                                                                                                                                             
   Superior mesenteric artery                                                   144 (33%)                                                                                          ---                                                                   
   Coeliac trunk                                                                188 (43%)                                                                                          ---                                                                   
   Hepatic artery                                                                25 (6%)                                                                                           ---                                                                   
   No                                                                           79 (18%)                                                                                           ---                                                                   
   Missing                                                                          6                                                                                              ---                                                                   
  Median follow-up time, months (95% CI)                                    34.3 (27.6--43.7)                       All patients were followed until death (maximum time observed=76.6) except five patients alive with a median follow-up equal to 10   

Abbreviations: CI=confidence interval; NA=not available; PS=performance status; WHO=World Health Organization. Bold values refer to significant *P*-values reflecting statistical significant difference for the parameter considered between the 2 cohorts.

Plus--minus values are means±s.d.

###### Univariate analysis of factors associated with overall survival

                                                     **Number of patients**  **Number of events**   **HR**   **95% CI**       ***P***
  ------------------------------------------------- ------------------------ ---------------------- -------- ---------------- ------------
  **Demographic parameters**                                                                                                  
  Age at inclusion, years                                     442            379                    1.013    1.003--1.024     **0.0148**
  Sex                                                                                                                          
   Male                                                       228            198                    1        ---              ---
   Female                                                     214            181                    0.915    0.748--1.120     0.3897
  **Pathological parameters**                                                                                                 
  Primary tumour site                                                                                                          
   Head--head and body                                        302            260                    1                          
   Body and/or tail                                           138            117                    0.951    0.764--1.183     0.6519
   Unknown                                                     2                                                               
  Histological grade                                                                                                           
   Well differentiated                                        107            89                     1        ---              ---
   Moderately differentiated                                   75            62                     1.106    0.799--1.530     ---
   Poorly differentiated                                       41            40                     1.939    1.331--2.825     **0.0021**
   Missing                                                    219                                                              
  Regional lymph node invasion                                                                                                 
   No                                                         258            222                    1        ---              ---
   Yes                                                        179            152                    0.954    0.776--1.174     0.6584
   Missing                                                     5             ---                    ---      ---              ---
  Arterial involvement                                                                                                         
   No                                                          10            7                      1        ---              ---
   Yes                                                        430            370                    0.635    0.299--1.345     0.2352
   Missing                                                     2             ---                    ---      ---              ---
  **Clinical parameters**                                                                                                     
  PS (WHO)                                                                                                                     
   0                                                          197            162                    1        ---              ---
   1                                                          203            179                    1.252    1.012--1.550     ---
   2                                                           31            30                     1.731    1.171--2.558     **0.0092**
   Missing                                                     11            ---                    ---      ---              ---
  Systolic blood pressure, mmHg                               252            222                    1.011    1.003 to 1.019   **0.0048**
  Diastolic blood pressure, mmHg                              260            222                    1.006    0.997--1.015     0.2176
  Diarrhoea                                                                                                                    
   No                                                         408            351                    1        ---              ---
   Yes                                                         31            27                     0.763    0.516--1.129     0.1763
   Missing                                                     3             ---                    ---      ---              ---
  Pain                                                                                                                         
   No                                                         186            155                    1        ---              ---
   Yes                                                        253            223                    1.199    0.976--1.472     **0.0834**
   Missing                                                     3             ---                    ---      ---              ---
  Jaundice                                                                                                                     
   No                                                         387            334                    1        ---              ---
   Yes                                                         51            44                     0.971    0.709--1.331     0.8550
   Missing                                                     4             ---                    ---      ---              ---
  Body Mass Index, kg m^−2^                                   434            372                    0.993    0.968--1.019     0.5831
  Body mass index, kg m^−**2**^                                                                                                
   Normal weight (18.5--25)                                   249            216                    1                          
   Underweight \<18.5                                          37            32                     1.041    0.718--1.510      
   Overweight (25--30)                                        114            97                     0.979    0.770--1.244      
   Obese⩾30                                                    34            27                     0.944    0.632--1.409     0.9822
   Missing                                                     8                                                               
  Percentage of weight loss                                   385            329                    1.009    0.993--1.025     0.2653
  **Biological parameters**                                                                                                   
  Haematological function                                                                                                      
   Neutrophils, mm^3^ (log-value)                             437            374                    1.473    0.818--2.654     0.1973
   Haemoglobin, g dl^−1^                                      442            379                    0.954    0.887--1.025     0.1976
   Platelets, mm^3^                                           438            376                    1.000    1.000--1.000     0.1442
  Biochemical                                                                                                                  
   Creatinine, *μ*mol l^−1^                                   440            377                    0.996    0.990--1.002     0.2153
   Creatinine clearance rate, ml min^−1^                      313            263                    1.000    0.996--1.005     0.9169
   Potassium, mmol l^−1^                                      422            363                    0.985    0.784--1.237     0.8950
   Total bilirubin, *μ*mol l^−1^ (log-value)                  440            377                    1.028    0.769--1.375     0.8517
   Alkaline phosphatase, UI l^−1^ (log-value)                 432            371                    1.147    0.789--1.667     0.4727
   Aspartate transaminase, UI l^−1^ (log-value)               438            375                    1.297    0.832--2.021     0.2510
   Alanine aminotransferase, UI l^−1^ (log-value)             436            373                    0.866    0.623--1.205     0.3930
   Lactate dehydrogenase, UI l^−1^ (log-value)                313            268                    1.089    0.599--1.983     0.7792
   Albumin, g l^−1^                                           393            336                    0.963    0.944--0.982     **0.0002**
   Proteinuria, g l^−1^                                       313            272                    0.988    0.968--1.007     0.2152
   Hypercalcemia, mmol l^−1^                                  347            301                    1.885    0.755--4.707     0.1748
   CA 19-9, UI (log-value)                                    411            359                    1.171    1.057--1.296     **0.0025**
  **Radiological parameters**                                                                                                 
  Tumour size, mm                                             422            362                    1.008    1.002--1.015     **0.0081**

Abbreviations: CI=confidence interval; HR=hazard ratio; PS=performance status; WHO=World Health Organization. Bold values refer to *P*-values \<0.1 highlighting parameters involved in the final multivariate construction as described in the statistical section.

###### Multivariate analysis of factors associated with overall survival (*N*=358)

                            **Number of patients**   **Number of death**   **HR**     **95% CI**   ***P***       **Internal validation BCA HR 95%**  **Max scores in nomogram**
  ------------------------- ------------------------ --------------------- -------- -------------- ------------ ------------------------------------ ----------------------------
  Age at diagnosis, years   358                      307                   1.013     1.000--1.025  **0.0478**               1.000--1.025             43
  Pain                                                                                                                                                
   No                       155                      130                   1              --       --                                                 
   Yes                      203                      177                   1.292     1.023--1.632  **0.0317**               1.046--1.657             16
  Albumin, g l^−1^          358                      307                   0.963     0.942--0.984  **0.0006**               0.942--0.988             96
  Tumour size, mm           358                      307                   1.008     1.001--1.015  **0.0214**               1.000--1.016             100
  CA 19-9, UI (log-value)   358                      307                   1.172     1.047--1.311  **0.0056**               1.039--1.306             80

Abbreviations: BCA=accelerated bootstrap confidence interval; CI=confidence interval; HR=hazard ratio. Bold values reflect that *P*-values are all significant \<0.05.

[^1]: These authors contributed equally to this work.
